1 of 1

Apurun

DLin-MC3-DMA (Ionizable)

DLin-MC3-DMA (Ionizable)

Regular price $466.00 USD
Regular price Sale price $466.00 USD
Sale Sold out
Shipping calculated at checkout.

DLin-MC3-DMA is an ionizable lipid employed in conjunction with other lipids to encapsulate RNA and DNA into lipid nanoparticles (LNPs). Studies have demonstrated that LNPs formulated with DLin-MC3-DMA can effectively deliver siRNA, resulting in a reduction of Factor VII levels in murine models. Furthermore, the delivery of BCR-ABL siRNA using DLin-MC3-DMA LNPs has shown promising outcomes in reducing the leukemic burden in a mouse model of chronic myeloid leukemia (CML). Additionally, research is underway to develop a formulation based on DLin-MC3-DMA for the treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in clinical settings

DLin-MC3-DMA Information

  • Molecular Formula: C43H79NO2
  • Molecular Weight (MW): 642.11
  • CAS Number: 1224606-06-7
  • Alternative Names: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate
  • Solubility: DLin-MC3-DMA is soluble in methanol, ethanol, chloroform, and DMSO.
  • Storage and Handling: It should be stored dry at -20 °C. Stock solutions must be kept frozen at -20 °C or below.

Background

DLin-MC3-DMA is an ionizable lipid employed in conjunction with other lipids to encapsulate RNA and DNA into lipid nanoparticles (LNPs). Studies have demonstrated that LNPs formulated with DLin-MC3-DMA can effectively deliver siRNA, resulting in a reduction of Factor VII levels in murine models. Furthermore, the delivery of BCR-ABL siRNA using DLin-MC3-DMA LNPs has shown promising outcomes in reducing the leukemic burden in a mouse model of chronic myeloid leukemia (CML). Additionally, research is underway to develop a formulation based on DLin-MC3-DMA for the treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in clinical settings

     

      View full details